Abstract:Background T2T is routine in RA, but no comparable standard has been defined for SLE. In 2015, the definition of Lupus Low Disease Activity State (LLDAS) was generated by Asia-Pacific Lupus Collaboration, and the preliminary validation demonstrated its attainment to be associated with improved outcomes in SLE. A SLEDAI-2K score lower than 4 is the main criteria for LLDAS. SSDM is an interactive mobile disease management application, including application systems for both the doctors and patients. The patients can perform self-assessment, including SLEDAI and medical records entry through the mobile application. The data is synchronized to the SSDM of authorized rheumatologists and stored in cloud database. Objectives To evaluate the patterns of T2T and related influential factors among SLE patients after applying SSDM in real world. Methods Patients were trained to master SSDM by rheumatologists in clinics. The first assessment for SLEDAI was performed as the baseline. Patients were required to perform repeated assessments after leaving the clinics. Results From July 2015 to Jan 2019, 1,090 SLE patients from 88 hospitals were followed up for more than 12 months through SSDM, and the results were summarized in Table 1. The ratio of T2T achievers was 52.84% (576/1,090) at the baseline and improved significantly to 68.35% (745/1,090) after a 12-month follow-up, p<0.01. Among T2T achievers at the baseline, 77.08% (444/576) maintained T2T, and 22.92% (132/576) relapsed. Of patients who didn’ t achieve T2Tat baseline, 58.56% (301/514) of the them achieve T2T after 12-month follow-up. The impact of the times of self-assessment for SLEDAI on T2T has been analyzed. The more frequent of the self-assessments being conducted by patients, the higher improvement of T2T rate will be. We performed linear regression analysis of variables in statistics and parameter estimation by least square method. The improvement of T2T rate(y) was positively correlated with times of self-assessment for SLEDAI(x) independently. The regression equation as “y = 0.0324x + 0.0226 R2 = 0.7717”, p<0.01. (Figure 1) Conclusion After proactive disease management via SSDM, the rate of T2T in SLE patients increased significantly. Patients with SLEDAI-2K≤4 score at baseline had a significantly higher retention rate. The patients who performed more self-assessments through SSDM had lower probability of relapse and higher rate of T2T maintaining and achievement. SSDM is a valuable tool for long term SLE follow-up through empowering patients.Table1: Baseline\Last follow-up Number % SLEDAI≤4 % SLEDAI≥5 % SLEDAI≤4 576 52.84% 444 77.08% 132 22.92% SLEDAI≥5 514 47.16% 301 58.56% 213 41.44% Total 1090 100% 745 68.35% 345 31.65%Figure 1 Disclosure of Interests None declared

Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab

Evaluation of Belimumab in Treatment of Chinese Childhood-Onset Systemic Lupus Erythematosus: a Prospective Analysis from a Multicentre Study

Belimumab 10 years later: how drug positioning has changed

Modelling long-term outcomes for patients with systemic lupus erythematosus

Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study

OP0250 INFLUENTIAL FACTORS IN PROMOTING TREAT-TO-TARGET FOR SYSTEMIC LUPUS ERYTHEMATOSUS VIA EMPOWERING PATIENTS: A COHORT STUDY FROM CHINA BY SMART SYSTEM OF DISEASE MANAGEMENT (SSDM)

Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?

Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?

Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study

Unveiling the dynamics of B lymphocytes in systemic lupus erythematosus patients treated with belimumab through longitudinal single-cell RNA sequencing

Navigating the landscape of SLE treatment: An expert viewpoint on the rationality and limitations of early biologic intervention

Predicting Lupus Low Disease Activity State and Remission in SLE: Novel Insights

Biologics in Systemic Lupus Erythematosus: Recent Evolutions and Benefits

Duration biased distribution of clinical and immunological phenotypes in active SLE

Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)

Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab

Association of Modified Systemic Lupus Erythematosus Responder Index Attainment with Long-Term Clinical Outcomes: A Five-Year Prospective Study

SLE‐DAS remission and low disease activity states discriminate drug from placebo and better health‐related quality of life

Belimumab in early systemic lupus erythematosus: A propensity score matching analysis

Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis

Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus